Literature DB >> 10621770

Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users.

D M Semple1, K P Ebmeier, M F Glabus, R E O'Carroll, E C Johnstone.   

Abstract

BACKGROUND: The use of MDMA ('ecstasy') is common among young people in Western countries. Animal models of MDMA toxicity suggest a loss of serotonergic neurons, and potentially implicate in the development of significant psychiatric morbidity in humans. AIMS: To test whether long-term use of MDMA can produce abnormalities in cerebral serotonin, but not dopamine, transporter binding measured by single photon emission computed tomography (SPECT).
METHOD: Ten male regular ecstasy users and 10 well-matched controls recruited from the same community sources participated in SPECT with the serotonin transporter (SERT) ligand [123I] beta-CIT. Dopamine transporter binding was determined from scans acquired 23 hours after injection of the tracer.
RESULTS: Ecstasy users showed a cortical reduction of SERT binding, particularly prominent in primary sensory-motor cortex, with normal dopamine transporter binding in lenticular nuclei.
CONCLUSIONS: This cross-sectional association study provides suggestive evidence for specific, at least temporary, serotonergic neurotoxicity of MDMA in humans.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10621770     DOI: 10.1192/bjp.175.1.63

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  57 in total

1.  Evidence for chronically altered serotonin function in the cerebral cortex of female 3,4-methylenedioxymethamphetamine polydrug users.

Authors:  Christina R Di Iorio; Tristan J Watkins; Mary S Dietrich; Aize Cao; Jennifer U Blackford; Baxter Rogers; Mohammed S Ansari; Ronald M Baldwin; Rui Li; Robert M Kessler; Ronald M Salomon; Margaret Benningfield; Ronald L Cowan
Journal:  Arch Gen Psychiatry       Date:  2011-12-05

2.  Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449-450.

Authors:  H R Sumnall; L Jerome; R Doblin; M C Mithoefer
Journal:  Psychopharmacology (Berl)       Date:  2003-11-21       Impact factor: 4.530

Review 3.  Clinical implications and methodological challenges in the study of the neuropsychological correlates of cannabis, stimulant, and opioid abuse.

Authors:  Antonio Verdejo-García; Francisca López-Torrecillas; Carmen Orozco Giménez; Miguel Pérez-García
Journal:  Neuropsychol Rev       Date:  2004-03       Impact factor: 7.444

4.  The Netherlands XTC Toxicity (NeXT) study: objectives and methods of a study investigating causality, course, and clinical relevance.

Authors:  Maartje M L De Win; Gerry Jager; Hylke K E Vervaeke; Thelma Schilt; Liesbeth Reneman; Jan Booij; Frank C Verhulst; Gerard J Den Heeten; Nick F Ramsey; Dirk J Korf; Wim Van den Brink
Journal:  Int J Methods Psychiatr Res       Date:  2005       Impact factor: 4.035

5.  "Ecstasy"-induced neurotoxicity: the contribution of functional brain imaging.

Authors:  M Schreckenberger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02       Impact factor: 9.236

6.  Occipital cortical proton MRS at 4 Tesla in human moderate MDMA polydrug users.

Authors:  Ronald L Cowan; Nicolas R Bolo; Mary Dietrich; Erica Haga; Scott E Lukas; Perry F Renshaw
Journal:  Psychiatry Res       Date:  2007-06-18       Impact factor: 3.222

7.  Chronic MDMA (ecstasy) use, cognition and mood.

Authors:  K McCardle; S Luebbers; J D Carter; R J Croft; C Stough
Journal:  Psychopharmacology (Berl)       Date:  2004-04-16       Impact factor: 4.530

Review 8.  Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function.

Authors:  M Isabel Colado; Esther O'Shea; A Richard Green
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

9.  Neuroimaging in human MDMA (Ecstasy) users.

Authors:  Ronald L Cowan; Deanne M Roberts; James M Joers
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

10.  Sleep apnea in young abstinent recreational MDMA ("ecstasy") consumers.

Authors:  Una D McCann; Francis P Sgambati; Alan R Schwartz; George A Ricaurte
Journal:  Neurology       Date:  2009-12-02       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.